Therapeutic Advances for MED13L Syndrome: Drug Repurposing Studies to Target Mitochondrial Dysfunction

Therapeutic Advances for MED13L Syndrome: Drug Repurposing Studies to Combat Mitochondrial Dysfunction focuses on identifying FDA-approved drugs that can restore cellular energy and function in cells affected by MED13L syndrome. The work responds to frequent caregiver reports of symptoms such as tiring easily, low muscle tone and overall lack of energy in individuals with MED13L syndrome, and is grounded in the observation that the MED13L gene is highly expressed in skeletal muscle and the central nervous system tissues with particularly high energy demands. Given that mitochondria are the principal energy producers of the cell, Campbell's research centers on assessing mitochondrial health in patient-derived samples and determining whether existing, approved therapeutics can ameliorate the mitochondrial dysfunction observed in these cells.

Campbell has demonstrated that mitochondrial dysfunction is present across all MED13L patient-derived samples tested to date. The dataset referenced comprises 12 skin biopsies collected in collaboration with Dr. Jen Bain at Columbia, and mitochondrial deficits were observed regardless of the specific MED13L variant. These consistent findings across samples provide a rationale for pursuing drug repurposing as a potentially expedited path from bench to bedside, since FDA-approved drugs have established safety profiles that can shorten the timeline for clinical evaluation compared with novel compound development.

Supported by a one-year Post-Doctoral Fellowship funded through the MED13L Foundation, Campbell's project entails systematic screening of candidate FDA-approved drugs for their capacity to restore mitochondrial energy production and cellular function in MED13L patient-derived cells. The immediate objective is to identify compounds that reliably improve measurable indices of mitochondrial performance thereby establishing proof-of-concept at the cellular level. The ultimate translational aim is to move promising candidates toward studies that can evaluate clinical benefit for people living with MED13L syndrome.

This research leverages patient-derived material and clinical collaboration to ensure that experimental findings remain closely tied to the lived manifestations of MED13L syndrome. By focusing on repurposing existing therapeutics, the project seeks to build a pragmatic path to potential treatments that could directly address energy-related symptoms reported by patients and caregivers. The fellowship-funded work represents an important early-stage investment in therapeutic discovery for a rare genetic condition and underscores the MED13L Foundation's commitment to moving promising laboratory findings toward interventions that could improve quality of life. Continued collaboration, rigorous cellular assays, and careful selection of candidate drugs are central to advancing this program from laboratory screening to eventual clinical translation.